GlassScriptPhysician profile
Merni T Stringfellow
NPI 1083777031
$3,494.47
in general payments reported to CMS, 2019-2025
26 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $641 · 2022: $808 · 2023: $887 · 2024: $856 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $406.24 | 2021-2023 | |
| Boston Scientific Corporation | $397.69 | 2022-2025 | Watchman Flx, Watchman Access System, General - Brady |
| Genentech USA, INC. | $229.37 | 2021-2022 | |
| Genzyme Corporation | $165.31 | 2023-2024 | |
| Novo Nordisk INC | $161.50 | 2022-2023 | |
| Medtronic, INC. | $160.30 | 2024 | Venaseal, Closurefast |
| Dexcom, INC. | $141.94 | 2023 | Dexcom G7 Gss (161) |
| Pharming Healthcare, INC. | $130.00 | 2024 | Ruconest |
| Neurocrine Biosciences, INC. | $128.78 | 2025 | |
| Abbvie INC. | $125.14 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2024 | Rexulti |
| Becton, Dickinson and Company | $123.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $116.28 | 2023 | Xarelto |
| Zoll Respicardia, INC. | $114.86 | 2021 | |
| Relievant Medsystems, INC. | $114.66 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $110.45 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Janssen Scientific Affairs, LLC | $105.90 | 2024 | Tremfya |
| Lilly USA, LLC | $95.52 | 2024 | |
| Hill-Rom Company, INC | $95.31 | 2021 | |
| Medline Industries LP | $88.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $82.52 | 2023 | Lokelma |
| Amgen INC. | $77.06 | 2024 | Uplizna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $75.59 | 2022 | |
| Coloplast Corp | $63.16 | 2021 | |
| Pfizer INC. | $32.25 | 2023 | |
| Glaxosmithkline, LLC. | $27.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merni Stringfellow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.